Changes in healthcare delivery are rapidly undermining traditional pharmaceutical commercial models. Customers are fewer and larger as hospitals consolidate into integrated delivery networks in the face of rising cost pressures, stiffer financial penalties and the imperatives of healthcare reform.
Dr Nicola Davies speaks to Mette Aagaard Hertz, Corporate Vice President at Novo Nordisk and Head of Human Resources in Research and Development, about pharma’s responsibility to maintain high standards in the fight against global health problems.
In January I was ‘treated’ by 10 HCPs in 7 days and more than 100 patients in 24 hours. The medics managed my physical state; the patients guided my psychological well-being, helping me reach decisions and an understanding more readily by sharing their information and experiences.
In the 3rd installment of Rethinking pharma, Dr Andree Bates talks about value creation and why she thinks pharma is giving its value away.
New columnist, Jeffrey Frick shares insights on the Chinese healthcare market.
The clinical trial process is a costly and integral part of bringing a drug to market, but does it have to be carried out the way it is currently? Is there a better way?
by Jeff Elton
Investment in real-world data, advanced analytics, and value-delivering services by life sciences companies is growing rapidly, particularly in the US and Europe. These companies are changing their commercial operating models as they attempt to improve patient and health system value outcomes.
by Marc Yates
China’s population has aged much faster than other populations, and this rapid aging poses challenges to healthcare, among which the most common are a surging healthcare expenditure and a rising difficulty in managing the 'iron triangle'.
We reflect on the past 12 months from the patient perspective – it has been a phenomenal year of successes, stories and surprises.
by David Laws
Customer Centricity, Communities of Practice, Big Data, Patient Centricity (probably), The Digital Organization and many more business model innovations have failed to take serious hold in pharma over the years.
With patient centricity firmly on the agenda, what is true patient centricity and how can we translate the intent to align more with action? I interviewed executives at Novo Nordisk and Sanofi to highlight the three key things to consider when seeking to be patient centric.
by Marc Yates
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
The healthcare delivery market is undergoing dramatic change, adapting to survive in a much tougher business climate we call Healthcare 2.0. This should prompt pharma organizations to reevaluate the assumptions on which they’ve built their commercial model, or they risk falling behind the curve.
Dr Andree Bates looks at the impact of precision medicine on pharma and the change in mindset necessary to fit this new reality.